PEAK6 Investments’s Kyntra Bio KYNB Stock Holding History

PEAK6 Investments’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,716	Closed	-$1.49M	–	4500
2020 Q1	$1.49M	Buy	1,716 +12	+0.7%	+$11.9K	0.01%	1236
2019 Q4	$1.83M	Buy	+1,704	New	+$1.74M	0.01%	1145

Other funds holding KYNB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PEAK6 Investments's KYNB Position: Q2 2020 in Review

PEAK6 Investments sold out of Kyntra Bio (KYNB) in Q2 2020, closing a stake of 531 shares — an estimated $461K sold.

PEAK6 Investments first reported a position in KYNB in Q4 2019 and held it in 2 quarters. The position peaked at $461K in Q1 2020. 194 funds tracked by Wall St. Rank hold KYNB as of Q2 2020.

PEAK6 Investments reported no remaining Kyntra Bio position as of Q2 2020 after selling out during the quarter.
PEAK6 Investments sold 531 Kyntra Bio shares in Q2 2020, an estimated $461K.
PEAK6 Investments first reported a position in Kyntra Bio in Q4 2019 and held it in 2 quarters.
PEAK6 Investments's Kyntra Bio position peaked at $461K in Q1 2020.
194 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2020.

Based on PEAK6 Investments's 13F filing for Q2 2020, filed 14 Aug 2020.